Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,822 matching trials from the live ClinicalTrials.gov search.
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Interactions Between Placebo Effects and Mindful Awareness State

NCT07108101
Conditions
Placebo Effect, Mindfulness, Pain, Transcranial Direct Current Stimulation (tDCS)
Interventions
tDCS stimulation (sham), tDCS stimulation (real), Mindful state induction, No minfulness induction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Hanover, New Hampshire
Conditions
Healthy Volunteers
Interventions
REGN1033(SAR391786), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Honolulu, Hawaii • Evansville, Indiana
Conditions
Covid19
Interventions
Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
11
States / cities
Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more
Conditions
Healthy Participants
Interventions
ALG-000184, Placebo, [14C]ALG-000184, [13C7,15N1]ALG-001075
Drug · Radiation
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Healthy
Interventions
sisunatovir, placebo, moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Conditions
Osteoarthritis
Interventions
Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428
Conditions
COVID-19, SARS-CoV-2
Interventions
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Completed Phase 2 Interventional Results available

AD109 Dose Finding in Mild to Moderate OSA

NCT04631107
Conditions
Obstructive Sleep Apnea
Interventions
AD109 dose1- A, AD109 dose2- B, Placebo- C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Conditions
Influenza
Interventions
CAIV-T
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Stamford, Connecticut
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Domvanalimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions
parsaclisib, ruxolitinib, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
Conditions
Diabetes
Interventions
Placebo, AGI-1067
Drug
Lead sponsor
AtheroGenics
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Stockbridge, Georgia • San Antonio, Texas
Conditions
Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
373
States / cities
Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more
Conditions
Sinusitis, Respiratory Tract Infections
Interventions
Amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Years to 11 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Bardstown, Kentucky • Gresham, Oregon • Philadelphia, Pennsylvania + 3 more
Conditions
Healthy Volunteers
Interventions
MAS825, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tempe, Arizona • Overland Park, Kansas
Conditions
COPD, Respiratory Disease, Lower Respiratory Disease, Pulmonary Disease, Healthy
Interventions
Vapendavir
Drug
Lead sponsor
Altesa Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Conditions
SCN2A Encephalopathy, SCN8A Encephalopathy
Interventions
PRAX-562
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Year to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more